Holen Sie sich die Stockscreener-App
4.11
2.38%
-0.10
Schlusskurs vom Vortag:
$4.21
Offen:
$4.25
24-Stunden-Volumen:
2.05M
Relative Volume:
0.52
Marktkapitalisierung:
$740.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-1.894
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
+24.54%
1M Leistung:
+7.87%
6M Leistung:
+146.10%
1J Leistung:
+27.64%
1-Tages-Spanne:
$4.06
$4.34
1-Wochen-Bereich:
$3.27
$4.34
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.10 | 759.95M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine announces NEJM publication of PM359 data - TipRanks
Prime Medicine (Nasdaq: PRME) reports first-in-human PM359 CGD data in NEJM study - Stock Titan
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine transferred with Neutral rating at JPMorgan - MSN
How interest rate cuts could boost Prime Medicine Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
How strong is Prime Medicine Inc. stock balance sheetRate Hike & Growth Oriented Trading Recommendations - newser.com
Prime Medicine Target of Unusually High Options Trading (NYSE:PRME) - MarketBeat
How Prime Medicine Inc. stock reacts to job market dataJuly 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - newser.com
Momentum divergence signals in Prime Medicine Inc. chartJuly 2025 Update & Trade Opportunity Analysis - newser.com
Prime Medicine’s Surprising Performance: Buy or Step Back? - StocksToTrade
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Published on: 2025-11-19 13:58:58 - newser.com
Prime Medicine (NASDAQ:PRME) Shares Down 5.8%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 6.1%Should You Sell? - MarketBeat
Technical signs of recovery in Prime Medicine Inc.July 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Tick level data insight on Prime Medicine Inc. volatilityJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Prime Medicine (NASDAQ:PRME) Shares Up 7.7%Should You Buy? - MarketBeat
Is Prime Medicine Inc. stock supported by strong fundamentalsEarnings Risk Summary & Real-Time Volume Analysis Alerts - newser.com
Is Prime Medicine Inc. stock a buy in volatile marketsWeekly Profit Analysis & High Return Stock Watch Alerts - newser.com
Published on: 2025-11-17 03:08:19 - newser.com
FY2025 EPS Estimate for Prime Medicine Increased by Analyst - MarketBeat
Can Prime Medicine Inc. stock outperform in 2025 bull market2025 Price Momentum & Fast Momentum Entry Tips - newser.com
How institutional ownership impacts Prime Medicine Inc. stockJuly 2025 Review & Entry Point Confirmation Alerts - newser.com
Combining price and volume data for Prime Medicine Inc.Market Trend Report & Capital Efficiency Focused Strategies - newser.com
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prime Medicine Inc-Aktie (PRME) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):